Document Detail

Natural history and therapy of AL cardiac amyloidosis.
MedLine Citation:
PMID:  25447844     Owner:  NLM     Status:  Publisher    
The natural history of immunoglobulin light chain associated amyloidosis (AL) is determined by the extent of cardiac involvement. Patients with cardiac AL and symptomatic heart failure have a median survival of approximately six months without successful treatment of the underlying plasma cell disorder The outcome in cardiac AL is determined by both the severity of cardiac involvement and the response to treatment. Staging systems using cardiac biomarkers, including NT- proBNP and troponin, have been found to be powerful predictors of prognosis and are used to guide treatment. Arrhythmias are common in cardiac AL and may lead to acute hemodynamic compromise. Sudden cardiac death, often due to pulseless electrical activity, is an important cause of early mortality. Supportive therapy for heart failure is usually limited to diuretics. Beta-blockers, ACE-inhibitors, and angiotensin receptor blockers are poorly tolerated in cardiac AL and should be avoided. Cardiac transplantation is controversial and reserved for highly selected patients with limited extracardiac involvement. The primary target of treatment in cardiac AL is obliteration of the plasma cell clone, using chemotherapy alone or combined with autologous stem cell transplantation. Despite the risk of early mortality, overall survival has improved with advances in disease modifying therapy. Earlier diagnosis and treatment of cardiac AL is crucial to improving survival.
Martha Grogan; Angela Dispenzieri
Related Documents :
2423974 - Internal cardiac defibrillation threshold: effects of acute ischemia.
11220454 - Preventing sudden death in coronary cardiomyopathy: implantable defibrillators lead the...
25491934 - Tachycardia pacing induces myocardial neovascularization and mobilizes circulating endo...
25485424 - Structured dictionaries for ischemia estimation in cardiac bold mri at rest.
1719494 - Pacemaker syndrome in a patient with ddd pacemaker for long qt syndrome.
17216124 - Redefining the normal angiogram using population-derived ranges for coronary size and s...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-12-2
Journal Detail:
Title:  Heart failure reviews     Volume:  -     ISSN:  1573-7322     ISO Abbreviation:  Heart Fail Rev     Publication Date:  2014 Dec 
Date Detail:
Created Date:  2014-12-2     Completed Date:  -     Revised Date:  2014-12-3    
Medline Journal Info:
Nlm Unique ID:  9612481     Medline TA:  Heart Fail Rev     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Characterization of urethane-dimethacrylate derivatives as alternative monomers for the restorative ...
Next Document:  Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver f...